Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.

Détails

ID Serval
serval:BIB_92FEAC3600A6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response.
Périodique
Respiratory research
Auteur⸱e⸱s
Robriquet L., Collet F., Tournoys A., Prangère T., Nevière R., Fourrier F., Guery B.P.
ISSN
1465-993X (Electronic)
ISSN-L
1465-9921
Statut éditorial
Publié
Date de publication
22/03/2006
Peer-reviewed
Oui
Volume
7
Numéro
1
Pages
41
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: epublish
Résumé
Acute lung injury (ALI) induces a coagulation/fibrinolysis imbalance and leads to fibrin deposition. The protein C pathway is an important regulator of the coagulation system and reduces the inflammatory response. The aim of the study was to examine the effects of recombinant human activated protein C (rhAPC) in the early phase of Pseudomonas aeruginosa (Pa)-induced lung injury.
The study was conducted in vivo on a rat model of Pa-induced ALI. Continuous intravenous (IV) rhAPC was administrated simultaneously with intratracheal (IT) Pa. We instilled into the airspaces a 5% bovine albumin solution with 1 mu(Ci of (125)I-albumin and injected IV 1 mu(Ci of (111)In-albumin to measure lung liquid clearance (LLC) and endothelial injury. Cytokines levels (TNFalpha and IL-6) and thrombin-antithrombin (TAT) complexes were measured in blood and bronchoalveolar lavage fluid (BALF) at 4 hours. Four groups were compared: control (CTR), pneumonia (PNP) receiving IT Pa (0.5 ml/kg of 1 x 10(9) cfu), APC: IV rhAPC (300 microg/kg/h), A-PNP: IT Pa /IV rhAPC.
Alveolar-capillary permeability was increased in the PNP versus the CTR group (0.28 +/- 0.08 vs. 0.03 +/- 0.01, p < 0.05). IV rhAPC in Pa-induced ALI led to further injury (0.47 +/- 0.17 vs. 0.28 +/- 0.08, p = 0.2). The LLC was significantly decreased in the A-PNP group compared to PNP group (9.1 +/- (4.3% vs. 33.4 +/- 2.6%, p < 0.05). The lung wet to dry weight ratio was significantly increased in the PNP group (4.62 +/- 0.31) compared to the CTR group (3.87 +/- 0.22, p < 0.05). IV rhAPC administration tends to increase this parameter in Pa-induced ALI (5.80 +/- 0.66, p = 0.07). These findings were associated with a loss of inflammatory response compartmentalization measured by TNFalpha and IL-6 systemic levels. TAT complexes in BALF were increased in the A-PNP group (23.17 +/- 2.89 ng/ml) compared to the CTR group (0.92 +/- 0.17 ng/ml, p < 0.05) and the PNP group (11.06 +/- 2.76 ng/ml, p < 0.05).
rhAPC reduces LLC following Pa-induced ALI and may influence pulmonary edema formation. The early massive fibrin formation is probably beneficial in ALI limiting both the extent of injury and permeability disorders.
Mots-clé
Animals, Antithrombin III/metabolism, Blood Coagulation/drug effects, Bronchoalveolar Lavage Fluid/chemistry, Bronchoalveolar Lavage Fluid/cytology, Bronchoalveolar Lavage Fluid/microbiology, Disease Models, Animal, Extravascular Lung Water/drug effects, Extravascular Lung Water/metabolism, Fibrinolytic Agents/administration & dosage, Fibrinolytic Agents/therapeutic use, Inflammation/metabolism, Inflammation/microbiology, Inflammation/pathology, Infusions, Intravenous, Interleukin-6/metabolism, Lung/metabolism, Lung/microbiology, Lung/pathology, Male, Neutrophils/drug effects, Neutrophils/pathology, Oxygen/metabolism, Peptide Hydrolases/metabolism, Pneumonia, Bacterial/metabolism, Pneumonia, Bacterial/microbiology, Pneumonia, Bacterial/pathology, Protein C/administration & dosage, Protein C/genetics, Protein C/pharmacology, Pseudomonas aeruginosa/isolation & purification, Rats, Rats, Sprague-Dawley, Recombinant Proteins/administration & dosage, Recombinant Proteins/pharmacology, Respiratory Distress Syndrome/metabolism, Respiratory Distress Syndrome/microbiology, Respiratory Distress Syndrome/pathology, Tumor Necrosis Factor-alpha/metabolism
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/04/2021 10:59
Dernière modification de la notice
17/07/2023 14:25
Données d'usage